The growing obesity epidemic in the United States is prompting a reevaluation of treatment options and a modern wave of medications—glucagon-like peptide-1 receptor agonists, or GLP-1s—are showing promise not just for adults, but increasingly for adolescents and even older adults. While initially approved for type 2 diabetes, these drugs are now being studied and utilized for weight management, with recent data suggesting both efficacy and a manageable safety profile across a wider age range. The conversation around GLP-1s for obesity is rapidly evolving, with healthcare providers and families weighing the benefits against potential risks.
Obesity rates remain stubbornly high, particularly among young people. According to recent data, approximately 1 in 5 children and adolescents in the U.S. Are affected by obesity, significantly increasing their risk of developing type 2 diabetes and other related health problems. The American Academy of Pediatrics highlights the need for both societal interventions and healthcare innovation to address this complex issue. GLP-1 receptor agonists represent one such advancement, gaining approval for use in adolescents as a treatment option.
Expanding Use Cases and Recent Findings
Traditionally used to manage blood sugar levels in individuals with type 2 diabetes, GLP-1s operate by mimicking the effects of a natural hormone that regulates appetite and insulin secretion. This leads to reduced food intake and improved glycemic control. A systematic review published in December 2025, analyzed randomized clinical trials evaluating the efficacy and safety of GLP-1 RAs in children and adolescents (<18 years) with obesity, prediabetes, or type 2 diabetes. The study, published in PubMed, found that these medications can lead to significant reductions in body weight, BMI, and hemoglobin A1c levels. The data analysis was completed between January and April 2025, drawing from research published up to February 28, 2025.
More recently, research has focused on the application of GLP-1s in older adults with obesity. While concerns about side effects and tolerability were initially present, emerging evidence suggests that these medications can be both safe and effective in this population. This is particularly significant given the increased health risks associated with obesity in older age, including cardiovascular disease, osteoarthritis, and certain types of cancer.
Navigating the Considerations for Younger Patients
The use of GLP-1s in pediatric and adolescent populations isn’t without its complexities. Pharmacy Practice News reports a cautious approach to expanding GLP-1 therapy for children, emphasizing the need for careful monitoring and individualized treatment plans. Experts are stressing the importance of addressing the underlying lifestyle factors that contribute to obesity, such as diet and physical activity, alongside pharmacological interventions. There’s also ongoing discussion about the potential for long-term effects and the need for further research to fully understand the risks and benefits.
Similarly, the question of whether college-age patients should utilize GLP-1s for weight loss is gaining attention. Spectrum News highlights the debate surrounding the use of these medications for cosmetic rather than medical reasons, and the potential for misuse or dependence.
Looking Ahead: Continued Research and Refined Guidelines
The landscape of obesity treatment is rapidly changing, and GLP-1s are poised to play an increasingly significant role. However, ongoing research is crucial to refine treatment guidelines, identify the most appropriate candidates for therapy, and monitor long-term outcomes. Diabetes In Control reports on the evolving understanding of metabolic risk and the potential for early intervention with GLP-1s in young adults, suggesting a shift towards proactive management of obesity-related health concerns.
The Food and Drug Administration (FDA) continues to monitor the safety and efficacy of these medications, and updates to prescribing information and guidelines are expected as new data become available. Healthcare providers are encouraged to stay informed about the latest research and to engage in shared decision-making with their patients, carefully considering the individual risks and benefits of GLP-1 therapy.
The next key development to watch for is the release of updated clinical practice guidelines from major medical organizations, anticipated in late 2026, which will likely provide more specific recommendations for the use of GLP-1s in different patient populations.
This is a developing story, and we encourage readers to share their thoughts and experiences in the comments below.
